Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

Published:2020-01-24 Issue:9 Volume:26 Page:2124-2130
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Strosberg Jonathan,Mizuno Nobumasa^ORCID,Doi Toshihiko,Grande Enrique,Delord Jean-Pierre^ORCID,Shapira-Frommer Ronnie,Bergsland Emily,Shah Manisha,Fakih Marwan,Takahashi Shunji,Piha-Paul Sarina A.,O'Neil Bert,Thomas Sajeve,Lolkema Martijn P.,Chen Menghui,Ibrahim Nageatte^ORCID,Norwood Kevin,Hadoux Julien^ORCID

Funder

Merck

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer;Respiratory Medicine and Research;2024-11

2. Clinical significance of positive resection margin for patients with rectal neuroendocrine tumors within 20 mm following initial endoscopic resection: A multi-center study;European Journal of Surgical Oncology;2024-11

3. Diagnosis and Management of Parathyroid Carcinoma;Clinical Pharmacology & Therapeutics;2024-09-05

4. Management of typical and atypical metastatic lung carcinoids: present and future perspectives;Clinical and Translational Oncology;2024-08-07

5. Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut;Cancers;2024-07-13